16 November 2026

Appendix 3Y – Change of Director's Interest Notice – Andrew Kerr

Cryosite Limited (ASX: **CTE**) (**Cryosite** or **Company**) refers to the attached Appendix 3Y – Change of Director's Interest Notice for Andrew Kerr.

The Company notes that the Appendix 3Y reflects the following additional indirect interests held by AMK Advisory Pty Ltd ATF AMK Advisory Trust, of which Mr Kerr is a director and shareholder:

- 400,000 unlisted options exercisable at A$0.90 each, expiring 6 November 2030;
- 300,000 unlisted options exercisable at A$1.10 each, expiring 6 November 2030;
- 200,000 unlisted options exercisable at A$1.20 each, expiring 6 November 2030; and
- 100,000 unlisted options exercisable at A$1.30 each, expiring 6 November 2030.

The interests were approved by shareholders at the 2025 Annual General Meeting and allotted on 22 October 2025, with the allotment disclosed in the Appendix 3G released on 23 October 2025. Due to an administrative oversight, the interests were not separately disclosed in an Appendix 3Y within the timeframe prescribed by ASX Listing Rule 3.19A.2. The interests have now been disclosed in the current Appendix 3Y.

The Company considers this to be an isolated incident and has reviewed its procedures to ensure that changes in Directors' interests, including indirect interests, are appropriately identified and notified within the required timeframe.

The Company and its Directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B, and the Company considers its current arrangements adequate to ensure ongoing compliance.

Authorised for lodgement by the Board of the Company.

—END—

Cryosite Ltd (ABN: 86 090 919 476)
Headquarters: 13a Ferndell Street, South Granville, NSW 2142
Secondary Facility: 100-104 Adderley Street West, Auburn, NSW, 2144
Tel: +61 (2) 8865 2000 | Email: corporate@cryosite.com | www.cryosite.com

About Cryosite

Cryosite is a unique Australian company and a world-class specialist in providing outsourced clinical trial and biological depot services.

Established in 2000, Cryosite is highly experienced in clinical trial logistics. Our team is comprised of highly qualified scientists and clinical trials experts who ensure complex clinical trials are conducted with seamless efficiency and safety.

We manage the importation, receipt, storage, distribution and reverse logistics of specialised ambient, cold, frozen, ultra-frozen, liquid nitrogen clinical trial, pharmaceutical and biological products. Cryosite's third party depot services are professional, reliable and compliant; our people are experts in their respective fields and are approachable, ethical and responsive to clients' needs.

To learn more, please visit our website or Cryosite's Investor Hub.

South Granville: Headquarters

13a Ferndell Street
South Granville, NSW, 2142
Building Area: ~1,800sqm
GMP, GWP licenced

Services include Clinical Trial and Biological:

- Storage
- Importation
- Receipt
- Labelling
- Distribution
- Secondary packaging
- Reverse logistics
- Expiry extension



Auburn: Secondary Facility

100-104 Adderley Street West
Auburn, NSW, 2144
~15 minutes' drive from South Granville
Building Area: ~2,100sqm (clearance 9.1m)

Services Include:

- Clinical trial and biological service expansion
- Medical devices
- Reverse logistics
- Pallet storage

Talk to us about your requirements – contact@cryosite.com



Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cryosite Limited
ABN	86 090 919 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Kerr
Date of last notice	23 February 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	AMK Advisory Pty Ltd ATF AMK Advisory Trust *Andrew Kerr is a director/shareholder of the trustee and beneficiary of the trust.*
Date of change	(5) to (8) 12 November 2026
No. of securities held prior to change AMK Advisory Pty Ltd ATF AMK Advisory Trust	(1) 400,000 unlisted options exercisable at A$0.90 each expiring 06 November 2030. (2) 300,000 unlisted options exercisable at A$1.10 each expiring 06 November 2030. (3) 200,000 unlisted options exercisable at A$1.20 each expiring 06 November 2030 (4) 100,000 unlisted options exercisable at A$1.30 each expiring 06 November 2030
Class	(5) to (8) Unlisted options
Number acquired	(5) to (8) 666,667 unlisted options
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(5) to (8) Nil
No. of securities held after change AMK Advisory Pty Ltd ATF AMK Advisory Trust	(1) 400,000 unlisted options exercisable at A$0.90 each expiring 06 November 2030. (2) 300,000 unlisted options exercisable at A$1.10 each expiring 06 November 2030. (3) 200,000 unlisted options exercisable at A$1.20 each expiring 06 November 2030. (4) 100,000 unlisted options exercisable at A$1.30 each expiring 06 November 2030. (5) 266,666 unlisted options exercisable at A$1.30 each expiring 26 February 2031. (6) 200,000 unlisted options exercisable at A$1.50 each expiring 26 February 2031. (7) 133,334 unlisted options exercisable at A$1.60 each expiring 26 February 2031. (8) 66,667 unlisted options exercisable at A$1.70 each expiring 26 February 2031.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(5) to (8) Issue of unquoted options under the Employee Option Plan following shareholder approval at the Company's Annual General Meeting on 22 October 2026.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.